NanoMed Market Analysis and Reports | Italy Conference Series

Market Analysis - NanoMed 2017

Global NanoMedicine Market Report:

Global nanomedicine market was valued at $78.54 billion in 2012, $214.2 billion in 2013 and $248.3 billion in 2014. The total market is projected to grow at a compound annual growth rate (CAGR) of 16.3% from 2014 through 2019 and reach $528 billion by 2019 and is anticipated to reach $344.0 billion by 2024, according to a new report by Grand View Research, Inc. According to a recent market research report released by Transparency Market Research, the global nanomedicine market is estimated to expand at a CAGR of 12.3% during the period between 2013 and 2019. The overall market was valued at US Transparency Market Research states that the global nanomedicine market, which had a valuation of US$111.10 billion in 2015, will expand at an excellent double-digit CAGR over the next few years and rise to a valuation of US$177.06 billion by 2019. In terms of application, the oncology segment is presently the dominant and is expected to retain its position over the next few years as well.

FACTS AND FIGURES:

  • Applications in the oncology field contributed US$42.34 bn to the global nanomedicine market’s revenues in 2015.
  • Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and are more cost-effective than conventional methods, in particular for cancer treatment.
  • As per the WHO factsheet, cancer is found to be one of the major causes of morbidity and mortality worldwide, with approximately 8.2 million cancer-related deaths and 14 million new cases in 2012. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.
  • North America led the industry in 2015, accounting for over 40% of revenue generated. Due to a number of key participants operating in this region which are involved in collaborative activities and research for incorporation of nanotechnology in conventional therapies is prenominal for this major share of North America in terms of revenue.
  • Moreover, an abundance of research publications and patent filings from European region with a share of about 25% in nanomedicine-related publications is supportive for considerable revenue generation expected from European economies as well.
  • Biopharmaceutical and medical devices companies are engaged actively in the development of novel products as demonstrated by the rise in the number of international partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies